Liposome-based cationic adjuvant formulations (CAF): past, present, and future

Dennis Christensen, Else Marie Agger, Lars Vibe Andreasen, Daniel Kirby, Peter Andersen, Yvonne Perrie

Research output: Contribution to journalArticle

Abstract

The use of liposomes as vaccine adjuvants has been investigated extensively over the last few decades. In particular, cationic liposomal adjuvants have drawn attention, with dimethyldioctadecylammonium (DDA) liposomes as a prominent candidate. However, cationic liposomes are, in general, not sufficiently immunostimulatory, which is why the combination of liposomes with immunostimulators has arisen as a strategy in the development of novel adjuvant systems in recent years. One such adjuvant system is CAF01. In this review, we summarize the immunological properties making CAF01 a promising versatile adjuvant system, which was developed to mediate protection against tuberculosis (TB) but, in addition, has shown promising protective efficacy against other infectious diseases requiring different immunological profiles. Further, we describe the stabilization properties that make CAF01 suitable in vaccine formulation for the developing world, which in addition to vaccine efficacy, are important prerequisites for any novel TB vaccine to reach global implementation. The encouraging nonclinical data led to a preclinical vaccine toxicology study of the TB model vaccine, Ag85B-ESAT-6/CAF01, that concluded that CAF01 has a satisfactory safety profile to advance the vaccine into phase I clinical trials, which are scheduled to start in 2009.
LanguageEnglish
Pages2-11
Number of pages10
JournalJournal of Liposome Research
Volume19
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

Liposomes
Vaccines
Tuberculosis Vaccines
Clinical Trials, Phase I
Toxicology
Communicable Diseases
Tuberculosis
Safety

Keywords

  • immunologic adjuvants
  • animals
  • humans
  • liposomes
  • quaternary ammonium compounds
  • tuberculosis
  • tuberculosis vaccines

Cite this

Christensen, Dennis ; Agger, Else Marie ; Andreasen, Lars Vibe ; Kirby, Daniel ; Andersen, Peter ; Perrie, Yvonne. / Liposome-based cationic adjuvant formulations (CAF) : past, present, and future. In: Journal of Liposome Research. 2009 ; Vol. 19, No. 1. pp. 2-11.
@article{cf8d33844a754f94b7bb94fa4d1d274c,
title = "Liposome-based cationic adjuvant formulations (CAF): past, present, and future",
abstract = "The use of liposomes as vaccine adjuvants has been investigated extensively over the last few decades. In particular, cationic liposomal adjuvants have drawn attention, with dimethyldioctadecylammonium (DDA) liposomes as a prominent candidate. However, cationic liposomes are, in general, not sufficiently immunostimulatory, which is why the combination of liposomes with immunostimulators has arisen as a strategy in the development of novel adjuvant systems in recent years. One such adjuvant system is CAF01. In this review, we summarize the immunological properties making CAF01 a promising versatile adjuvant system, which was developed to mediate protection against tuberculosis (TB) but, in addition, has shown promising protective efficacy against other infectious diseases requiring different immunological profiles. Further, we describe the stabilization properties that make CAF01 suitable in vaccine formulation for the developing world, which in addition to vaccine efficacy, are important prerequisites for any novel TB vaccine to reach global implementation. The encouraging nonclinical data led to a preclinical vaccine toxicology study of the TB model vaccine, Ag85B-ESAT-6/CAF01, that concluded that CAF01 has a satisfactory safety profile to advance the vaccine into phase I clinical trials, which are scheduled to start in 2009.",
keywords = "immunologic adjuvants, animals, humans, liposomes, quaternary ammonium compounds, tuberculosis, tuberculosis vaccines",
author = "Dennis Christensen and Agger, {Else Marie} and Andreasen, {Lars Vibe} and Daniel Kirby and Peter Andersen and Yvonne Perrie",
year = "2009",
doi = "10.1080/08982100902726820",
language = "English",
volume = "19",
pages = "2--11",
journal = "Journal of Liposome Research",
issn = "0898-2104",
publisher = "Informa Healthcare",
number = "1",

}

Liposome-based cationic adjuvant formulations (CAF) : past, present, and future. / Christensen, Dennis; Agger, Else Marie; Andreasen, Lars Vibe; Kirby, Daniel; Andersen, Peter; Perrie, Yvonne.

In: Journal of Liposome Research, Vol. 19, No. 1, 2009, p. 2-11.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Liposome-based cationic adjuvant formulations (CAF)

T2 - Journal of Liposome Research

AU - Christensen, Dennis

AU - Agger, Else Marie

AU - Andreasen, Lars Vibe

AU - Kirby, Daniel

AU - Andersen, Peter

AU - Perrie, Yvonne

PY - 2009

Y1 - 2009

N2 - The use of liposomes as vaccine adjuvants has been investigated extensively over the last few decades. In particular, cationic liposomal adjuvants have drawn attention, with dimethyldioctadecylammonium (DDA) liposomes as a prominent candidate. However, cationic liposomes are, in general, not sufficiently immunostimulatory, which is why the combination of liposomes with immunostimulators has arisen as a strategy in the development of novel adjuvant systems in recent years. One such adjuvant system is CAF01. In this review, we summarize the immunological properties making CAF01 a promising versatile adjuvant system, which was developed to mediate protection against tuberculosis (TB) but, in addition, has shown promising protective efficacy against other infectious diseases requiring different immunological profiles. Further, we describe the stabilization properties that make CAF01 suitable in vaccine formulation for the developing world, which in addition to vaccine efficacy, are important prerequisites for any novel TB vaccine to reach global implementation. The encouraging nonclinical data led to a preclinical vaccine toxicology study of the TB model vaccine, Ag85B-ESAT-6/CAF01, that concluded that CAF01 has a satisfactory safety profile to advance the vaccine into phase I clinical trials, which are scheduled to start in 2009.

AB - The use of liposomes as vaccine adjuvants has been investigated extensively over the last few decades. In particular, cationic liposomal adjuvants have drawn attention, with dimethyldioctadecylammonium (DDA) liposomes as a prominent candidate. However, cationic liposomes are, in general, not sufficiently immunostimulatory, which is why the combination of liposomes with immunostimulators has arisen as a strategy in the development of novel adjuvant systems in recent years. One such adjuvant system is CAF01. In this review, we summarize the immunological properties making CAF01 a promising versatile adjuvant system, which was developed to mediate protection against tuberculosis (TB) but, in addition, has shown promising protective efficacy against other infectious diseases requiring different immunological profiles. Further, we describe the stabilization properties that make CAF01 suitable in vaccine formulation for the developing world, which in addition to vaccine efficacy, are important prerequisites for any novel TB vaccine to reach global implementation. The encouraging nonclinical data led to a preclinical vaccine toxicology study of the TB model vaccine, Ag85B-ESAT-6/CAF01, that concluded that CAF01 has a satisfactory safety profile to advance the vaccine into phase I clinical trials, which are scheduled to start in 2009.

KW - immunologic adjuvants

KW - animals

KW - humans

KW - liposomes

KW - quaternary ammonium compounds

KW - tuberculosis

KW - tuberculosis vaccines

UR - http://www.scopus.com/inward/record.url?scp=68349132242&partnerID=8YFLogxK

UR - http://informahealthcare.com/doi/abs/10.1080/08982100902726820

U2 - 10.1080/08982100902726820

DO - 10.1080/08982100902726820

M3 - Article

VL - 19

SP - 2

EP - 11

JO - Journal of Liposome Research

JF - Journal of Liposome Research

SN - 0898-2104

IS - 1

ER -